Skip to main content

Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics

Guest edited by Dr. Felice Gragnano, Dr. Arturo Cesaro, and Prof. Paolo Calabrò from the University of Campania “Luigi Vanvitelli”, Caserta, Italy

New Content ItemLipids in Health and Disease invites you to contribute a manuscript to our new thematic series, "Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics". 

People who maintain ideal cardiovascular health have high life expectancy and low lifetime risk of disabling and life-threatening medical conditions. Therefore, the identification and adoption of novel strategies to pursue ideal cardiovascular health represent a vital opportunity to improve the prevention and treatment of cardiovascular diseases. Because atherogenic lipids and lipoproteins play a causal role in the initiation and progression of endothelial dysfunction and atherosclerosis, maintenance of optimal lipid levels is necessary to attain ideal cardiovascular health status.

Evidence from Mendelian randomization studies and randomized trials has conclusively demonstrated that lower low-density lipoprotein cholesterol (LDL-C) can effectively reduce cardiovascular risks. Additional benefits may derive from lowering triglycerides and lipoprotein(a) and elevating serum levels and activity of high-density lipoprotein cholesterol (HDL-C).

To date, numerous challenges and controversies exist concerning the cumulative effect of lipid-carrying lipoproteins on cardiovascular health, the magnitude of the clinical benefit obtained by achieving and maintaining optimal lipid levels and the best timing to initiate lipid-modifying strategies to mitigate cardiovascular risk.

We invite you to contribute to this new thematic series of Lipids in Health and Disease, which will focus on the link between lipids and cardiovascular health from mechanisms to therapeutics, emphasizing the importance of an individualized approach in clinical and preclinical studies design (so-called “precision medicine”).

We warmly welcome articles, including original research, narrative reviews, systematic reviews and meta-analyses, mini-reviews, and commentary on this relevant and rapidly evolving topic.


Lipids, lipoproteins, LDL, HDL, lipoprotein(a), triglycerides, atherosclerosis, endothelial dysfunction, cardiovascular disease, cardiometabolic disease.

All submissions should be made by 31 December 2023.


  • Mechanisms and molecular pathways affecting lipids and lipoproteins metabolism
  • Impact of genetics on lipid and metabolic disorders
  • Effect of lipid-lowering therapy on cardiovascular health
  • Lipid targets in cardiovascular disease
  • Future perspective and novel therapeutic strategies in dyslipidemias

Questions to be answered:

  • What are the novel mechanisms involved in the regulation of lipid metabolism?
  • Can genetic evaluation guide decision-making in the management of lipid disorders?
  • Should lipid targets be individualized according to patient risk profile?
  • What is the mechanistic link between cholesterol and triglyceride disorders?
  • How do non-LDL cholesterol targets affect clinicians’ decisions in contemporary practice?
  • What are the following steps to be taken to reduce the residual cardiovascular burden?

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process.

Please find out more about our journal and its policies, here. Submission guidelines can be found here, and please submit to the series via our submission system.

  1. Acute myocardial infarction (AMI) is characterized by inflammation, oxidative stress, and atherosclerosis, contributing to increased mortality risk. High-density lipoprotein (HDL) takes a crucial part in mitig...

    Authors: Congzhuo Jia, Wanying Wu, Huan Lu, Jin Liu, Shiqun Chen, Guoxiao Liang, Yang Zhou, Sijia Yu, Linfang Qiao, Jinming Chen, Ning Tan, Yong Liu and Jiyan Chen
    Citation: Lipids in Health and Disease 2024 23:86
  2. The study aimed to investigate the association between nonalcoholic fatty liver disease (NAFLD) and ischemic stroke events after revascularization in patients with Moyamoya disease (MMD).

    Authors: Bojian Zhang, Junsheng Li, Chaofan Zeng, Chuming Tao, Qiheng He, Chenglong Liu, Zhiyao Zheng, Zhikang Zhao, Siqi Mou, Wei Sun, Jia Wang, Qian Zhang, Rong Wang, Yan Zhang, Peicong Ge and Dong Zhang
    Citation: Lipids in Health and Disease 2024 23:80
  3. Atherosclerosis (AS) is a persistent inflammatory condition triggered and exacerbated by several factors including lipid accumulation, endothelial dysfunction and macrophages infiltration. Nobiletin (NOB) has ...

    Authors: Heng Wang, Qinqin Tian, Ruijing Zhang, Qiujing Du, Jie Hu, Tingting Gao, Siqi Gao, Keyi Fan, Xing Cheng, Sheng Yan, Guoping Zheng and Honglin Dong
    Citation: Lipids in Health and Disease 2024 23:76
  4. Whether iron intake can affect cardiovascular disease (CVD) and dyslipidemia is controversial. However, few studies have focused on reducing the risk of CVD in people at risk for dyslipidemia. This study explo...

    Authors: Min Cui, Hao Wu, Hanmo Zhang, Liping Wei and Xin Qi
    Citation: Lipids in Health and Disease 2024 23:67
  5. Cardiovascular disease (CVD) is associated with inflammation and abnormal lipid metabolism. However, a single inflammatory index or a single lipid index cannot accurately predict the prognosis of CVD independe...

    Authors: Yu Gao, Miyuan Wang, Ruiting Wang, Jinchi Jiang, Yueyao Hu, Wei Wang, Yong Wang and Haijing Li
    Citation: Lipids in Health and Disease 2024 23:66
  6. To investigate the baseline and six-month follow-up data of the main lipid indices as well as low-density lipoprotein cholesterol (LDL-C) target goal attainment in accordance with the current guidelines among ...

    Authors: Zhong Chen, Shijia Jin and Yifan Zhang
    Citation: Lipids in Health and Disease 2024 23:62
  7. The Triglyceride glucose-body mass index (TyG-BMI) and hemoglobin glycation index (HGI) are well-established surrogate markers for insulin resistance. Nevertheless, the extent to which these markers offer addi...

    Authors: Rupeng Wang, Ce Chen, Guiyu Xu and Zening Jin
    Citation: Lipids in Health and Disease 2024 23:53
  8. Myocardial ischemia–reperfusion injury (MIRI) is widespread in the treatment of ischemic heart disease, and its treatment options are currently limited. Adiponectin (APN) is an adipocytokine with cardioprotect...

    Authors: Hongyi Yue, Qunhui Zhang, Senhao Chang, Xinjie Zhao, Mengjie Wang and Wenhua Li
    Citation: Lipids in Health and Disease 2024 23:51
  9. Remnant cholesterol (RC) represents a low-cost and readily measured lipid index that contributes significantly to residual cardiovascular disease risk. The triglyceride-glucose (TyG) index exhibits a significa...

    Authors: Xiaosheng Wu, Weiping Qiu, Houlin He, Guojun Zhao and Jianling Liu
    Citation: Lipids in Health and Disease 2024 23:45
  10. The aim was to establish a 10-year dyslipidemia incidence model, investigating novel anthropometric indices using exploratory regression and data mining.

    Authors: Alireza Takhttavous, Maryam Saberi-Karimian, Somayeh Ghiasi Hafezi, Habibollah Esmaily, Marzieh Hosseini, Gordon A. Ferns, Elham Amirfakhrian, Mark Ghamsary, Majid Ghayour-Mobarhan and Maryam Alinezhad-Namaghi
    Citation: Lipids in Health and Disease 2024 23:33
  11. Current guidelines are debated when it comes to starting anticoagulant therapy in patients with non-valvular atrial fibrillation (NVAF) and low CHA2DS2-VASc scores (1–2 in women and 0–1 in men). However, these in...

    Authors: Kamila Kamili, Tingting Zheng, Chaodi Luo, Xuan Wang and Gang Tian
    Citation: Lipids in Health and Disease 2024 23:22
  12. Numerous studies have affirmed a robust correlation between residual cholesterol (RC) and the occurrence of cardiovascular disease (CVD). However, the current body of literature fails to adequately address the...

    Authors: Mengjie Zhao, Mengli Xiao, Qin Tan, Jinjin Ji and Fang Lu
    Citation: Lipids in Health and Disease 2024 23:19
  13. Cardiovascular diseases (CVD) is the leading cause of death among maintenance hemodialysis patients, with dyslipidemia being a prevalent complication. The paradoxical relationship between cardiovascular outcom...

    Authors: Lin Lin, Jie Teng, Yiqin Shi, Qiwen Xie, Bo Shen, Fangfang Xiang, Xuesen Cao, Xiaoqiang Ding, Xialian Xu and Zhen Zhang
    Citation: Lipids in Health and Disease 2024 23:15
  14. Reducing circulating lipid levels is the centerpiece of strategies for preventing and treating atherosclerotic cardiovascular disease (ASCVD). Despite many available lipid-lowering medications, a substantial r...

    Authors: Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni and Fei Luo
    Citation: Lipids in Health and Disease 2024 23:14
  15. Lipin family members in mammals include lipins 1, 2, and 3. Lipin family proteins play a crucial role in lipid metabolism due to their bifunctionality as both transcriptional coregulators and phosphatidate pho...

    Authors: Zerui Ding, Hongyu Song and Fang Wang
    Citation: Lipids in Health and Disease 2023 22:196
  16. Secreted frizzled-related protein 5 (SFRP5) is a member of the SFRP family that is known for its potent anti-inflammatory properties. Nevertheless, little is known regarding the relevance of SFRP5 in coronary ...

    Authors: Lin Jia, Shimei Shang, Yu Yang, Jian Zhang and Xianhe Lin
    Citation: Lipids in Health and Disease 2023 22:194
  17. The evidence on the relationship between remnant cholesterol (RC) and stroke remains controversial. Therefore, this study aimed to explore the relationship between RC and stroke risk in a Chinese population of...

    Authors: Yuanqing Wang, Fubing Zha, Yong Han, Ying Cai, Miaoling Chen, Cui Yang, Xiaodong Cai, Haofei Hu, Changchun Cao and Jiao Luo
    Citation: Lipids in Health and Disease 2023 22:181
  18. Data are limited on the relationship between cardiovascular disease (CVD) and the combinational indices of lipid accumulation product (LAP), triglyceride-glucose index (TyG), and visceral adiposity index (VAI)...

    Authors: Alireza Jafari, Hamid Najafipour, Mitra Shadkam and Sina Aminizadeh
    Citation: Lipids in Health and Disease 2023 22:169
  19. Controlling cholesterol levels is one of the primary goals of preventing atherosclerotic plaque progression in patients undergoing coronary artery bypass graft (CABG) surgery. This study aimed to investigate t...

    Authors: Aryan Ayati, Kasra Akbari, Akbar Shafiee, Arezou Zoroufian, Arash Jalali, Sahar Samimi, Mina Pashang, Kaveh Hosseini, Jamshid Bagheri and Farzad Masoudkabir
    Citation: Lipids in Health and Disease 2023 22:163
  20. Oxylipins, the oxidative metabolites of polyunsaturated fatty acids (PUFAs), serve as key mediators of oxidative stress, inflammatory responses, and vasoactive reactions in vivo. Our previous work has establis...

    Authors: Tong Liu, Inci Dogan, Michael Rothe, Evgenij Potapov, Felix Schoenrath, Maik Gollasch, Friedrich C. Luft and Benjamin Gollasch
    Citation: Lipids in Health and Disease 2023 22:138
  21. Accumulating evidence indicated that apolipoprotein B (apoB) was the principal lipid determinant of coronary artery disease (CAD). Nevertheless, the connection between apoB and angiographic progression of CAD ...

    Authors: Xing Shui, Zheqi Wen, Ruimin Dong, Zefeng Chen, Leile Tang, Wenyu Tang, Zhen Wu and Lin Chen
    Citation: Lipids in Health and Disease 2023 22:125
  22. Patients with multi-vessel coronary artery disease (MV-CAD) have poorer clinical outcomes than those with single-vessel coronary artery disease (SV-CAD). Solid evidence underlines that high-density lipoprotein...

    Authors: Jiaqi Chen, Kangxiang Wu, Wanchun Cao, Jianan Shao and Mingyuan Huang
    Citation: Lipids in Health and Disease 2023 22:121
  23. Generally, low-density lipoprotein (LDL) particle size can be inferred from the LDL cholesterol concentration to total apolipoprotein B concentration ratio (LDL-C/ApoB ratio, hereinafter called LAR), which is ...

    Authors: Li Xiao, Kerui Zhang, Fang Wang, Min Wang, Qingxia Huang, Chenchen Wei and Zhongshan Gou
    Citation: Lipids in Health and Disease 2023 22:104
  24. A lthough the triglyceride-glucose (TyG) index has been shown to closely correlate with cardiometabolic outcomes and predict cardiovascular events in many groups, it remains unclear whether obese status in you...

    Authors: Weihua Chen, Shan Ding, Jiabin Tu, Guitao Xiao, Kaihong Chen, Yanbin Zhang, Rongchong Huang and Ying Liao
    Citation: Lipids in Health and Disease 2023 22:65
  25. The challenging rigorous management of hypercholesterolemia promotes referral to specialized units. This study explored the need, based on referral rate and cardiovascular (CV) risk factor control in patients ...

    Authors: Enric Serra-Planas
    Citation: Lipids in Health and Disease 2023 22:62
  26. Coronary artery calcification (CAC) is a potential risk marker of coronary atherosclerosis that has high specificity and sensitivity. However, the association between high-density lipoprotein cholesterol (HDL-...

    Authors: Farshad Abedi, Masoumeh Sadeghi, Navid Omidkhoda, Theodoros Kelesidis, Javad Ramezani, Sara Samadi and Amir Hooshang Mohammadpour
    Citation: Lipids in Health and Disease 2023 22:60
  27. The long-term excessive intake of exogenous cholesterol can lead to abnormally elevated blood lipid levels and induce cardiovascular and cerebrovascular diseases. However, the influence and relevance of exogen...

    Authors: Xichao Yu, Xue Ding, Han Feng, Yunhui Bi, Yu Li, Jinjun Shan and Huimin Bian
    Citation: Lipids in Health and Disease 2023 22:51
  28. High serum NEFA and GDF-15 are risk factors for CAD and have been linked to detrimental cardiovascular events. It has been hypothesized that hyperuricemia causes CAD via the oxidative metabolism and inflammati...

    Authors: Jingru Cheng, Yongnan Lyu, Yufeng Mei, Qian Chen, Hang Liu and Yan Li
    Citation: Lipids in Health and Disease 2023 22:31